Featuring a slide presentation and related discussion from Prof Constantine Tam, including the following topics:

• Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia (CLL): Results from the randomized CLL17 trial (0:00)
• Six-year follow-up data from the Phase III SEQUOIA trial of zanubrutinib for patients with treatment-naïve CLL and those with del(17p) CLL not randomly assigned (4:59)
• Primary endpoint analysis of the randomized STAIR trial of time-limited acalabrutinib monotherapy for frail patients with previously untreated CLL (7:25)
• Safety analyses of acalabrutinib/venetoclax (AV) or AV in combination with obinutuzumab for previously untreated CLL (10:50)
• Three-year results with zanubrutinib combined with venetoclax in arm D of the Phase III SEQUOIA trial for treatment-naïve CLL (17:15)
• Early-phase data with sonrotoclax combinations as front-line treatment of CLL (19:12)
• Pirtobrutinib for treatment-naïve and relapsed/refractory CLL/small lymphocytic lymphoma: Results from the Phase III BRUIN CLL-314 and BRUIN CLL-313 trials (23:27)
• Long-term extension (LTE1) results from the Phase III ALPINE trial of zanubrutinib versus ibrutinib in patients with relapsed/refractory CLL or small lymphocytic lymphoma (R/R CLL/SLL) (28:53)
• Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with R/R CLL/SLL from the ongoing phase 1 CaDAnCe-101 study (30:35)
• Real-world outcomes of lisocabtagene maraleucel in CLL (33:04)

CME information and select publications